ROS1 GENE TESTING FOR LUNG CANCER
- ROS1 gene is a proto-oncogene which belongs to the subfamily of tyrosine kinase insulin receptor genes.
- ROS protein plays an important role in cell growth and cell specialization.
- Mutations in the ROS1 gene can lead to a type of lung cancer known as non-small cell lung cancer (NSCLC)
- ROS1 gene testing is done in patients who are ALK negative
- Prognosis and prediction of response to Crizotinib.
- Monitor progression of the disease in NSCLC patients.
- ROS1 gene mutation are more common in lung cancer patients who are non smokers and relatively young (average age of 50 years).
- ROS1 mutations have been also linked to cholangiocarcinoma (bile duct cancer) and glioblastoma multiform, a type of brain cancer.
MET GENE TESTING FOR LUNG CANCER
- The MET protein is a receptor kinase that stimulates tyrosine-kinase activity which leads to activation of signalling pathways associated with cell growth and survival.
- MET protein over expression leads to tumor growth and unfavourable prognosis in patients with lung adenocarcinoma.
- Met gene testing is done for the prognosis & cause of drug resistance to anti- EGFR TKI
- Monitor progression of the disease in lung carcinoma patients.
- Patients with non-small cell lung cancer and EGFR-activating mutations, which increase sensitivity to tyrosine kinase inhibitor (TKI) therapy, may be resistant to TKI therapy in the presence of MET oncogene amplification
- MET gene testing by Fish is a confirmatory technique used for the MET gene amplification.
- It identifies a small but clinically important subgroup of gastric cancer patients who are likely to respond to MET-TKIs.